Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.

Pharmacogenomics - 1 Jul 2017

Daud Aizati N A, Bergman Jorieke E H, Kerstjens-Frederikse Wilhelmina S, van der Vlies Pieter, Hak Eelko, Berger Rolf M F, Groen Henk, Wilffert Bob

Abstract excerpt

AIM: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors. METHODS: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal Development
Share to Heart Defects, Congenital

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Infant, Newborn

Share to Maternal Exposure

Share to Pharmacogenomic Variants

Share to Pregnancy

Share to Prenatal Exposure Delayed Effects

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 28639488
DOI: 10.2217/pgs-2017-0036

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study.PMID 28639488Read ↗

Association between Maternal Drug Use and Cytochrome P450 Genetic Polymorphisms and the Risk of Congenital Heart Defects in Offspring.Semantic proximity Read ↗

Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study.Semantic proximity Read ↗

Pharmacogenetics of drug-induced birth defects: what is known so far?Semantic proximity Read ↗

Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the childSemantic proximity Read ↗

Antiepileptic medication during pregnancy: does fetal genotype affect outcome?Semantic proximity Read ↗

MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs.Semantic proximity Read ↗

Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.Semantic proximity Read ↗

Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors pharmacogenetics during pregnancy and lactation.Semantic proximity Read ↗

Maternal medication use, fetal 3435 C>T polymorphism of the ABCB1 gene, and risk of isolated septal defects in a Han Chinese population.Semantic proximity Read ↗

Pharmacogenetics to Predict Adverse Events Associated With Antidepressants.Semantic proximity Read ↗

Associations and interaction effects of maternal smoking and genetic polymorphisms of cytochrome P450 genes with risk of congenital heart disease in offspring: A case-control study.Semantic proximity Read ↗

Association Between Methylphenidate and Amphetamine Use in Pregnancy and Risk of Congenital MalformationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.